Dizal (Jiangsu) Pharmaceutical Co. Ltd.

2 trials 2 recruiting Commercial sponsor

Filter these 2 trials by condition, phase, country and more.

Open in Search →

2 Registered trials

2 Recruiting

0 Completed trials

9 Countries active

7 Unique IMPs

N/A Results reported

Phase III

Top indications

B-cell small lymphocytic lymphoma 1

Top IMPs

[(2S,5S)-5-{4-AMINO-5-[4-(2,3-DIFLUOROPHENOXY)PHENYL]IMIDAZO[5,1-F][1,2,4]TRIAZIN-7-YL}OXAN-2-YL]METHANOL 1 BENDAMUSTINE HYDROCHLORIDE 1 CARBOPLATIN 1 IDELALISIB 1 PEMETREXED 1 RITUXIMAB 1 SUNVOZERTINIB 1

All trials

2 total

A Phase 3 Study of DZD8586 versus Investigator’s Choice in r/r CLL/SLL Recruiting

2025-522669-32-00 Phase III 2 countries [(2S,5S)-5-{4-AMINO-5-[4-(2,3-DIFLUOROPHENOXY)PHENYL]IMIDAZO[5,1-F][1,2,4]TRIAZI…
A Phase 3, Open-Label, Randomized, Multi-Center Study of DZD9008 versus Platinum-Based Doublet Chemotherapy as First-Line Treatment for Pati… Recruiting

2022-502959-54-00 Phase III 9 countries CARBOPLATIN; PEMETREXED; SUNVOZERTINIB

Showing 1–2 of 2 trials

← All sponsors A–Z